2 Sources
[1]
Nexentis orders molecules for testing in drug discovery program By Investing.com
NESS ZIONA, Israel - Nexentis Technologies Inc. (NASDAQ:NXTS) announced today that its subsidiary MitoCareX Bio Ltd. has ordered molecules for planned laboratory testing following computational analysis of earlier screening results. The molecules were selected after additional computational
[2]
Nexentis Technologies Inc. And Boltz, PBC Advance Drug-Discovery Initiative With MitoCareX Bio Ltd
Nexentis Technologies Inc. announced that its wholly owned subsidiary, MitoCareX Bio Ltd., has selected and ordered molecules for planned in-vitro evaluation following further computational prioritization of preliminary findings from its previously announced screening work. The development follows
Share
Copy Link
Nexentis Technologies has taken a step from computer screens toward the lab bench: its wholly owned subsidiary MitoCareX Bio has selected and ordered molecules for planned laboratory testing in a drug-discovery program
1
2
. The experiments are still plans, with no work started.The work sits under a drug-discovery initiative between MitoCareX Bio and Boltz, a public-benefit AI research lab working on biomolecular foundation models. The initiative pairs MitoCareX's discovery work with Boltz's AI models to find potential small-molecule starting points for chosen programs
1
2
.The selection came after additional computational prioritization of results from an initial screening stage finished on October 29, 2026
1
2
. The company described the preliminary predictions at the time as encouraging for further analysis and experimental work2
.The stated purpose is gathering evidence to guide a decision about which molecules, if any, deserve further work
1
2
.The gap between the announcement and the lab is wide for now. The molecules have not been received, testing has not begun, and the company gave no timeline for either
1
2
. The company itself cautions that the computational predictions remain experimentally unvalidated and that ordering molecules is no evidence any of them have biological activity1
2
.Related Stories
Summarized by
Navi
22 Jun 2026•Technology
27 Dec 2024•Business and Economy

04 Sept 2024
